Company comparison
Exscientia vs AlphaSense
Radar profile, momentum bars, and stack placement side by side.
Exscientia
Not scored
momentum
AlphaSense
Not scored
momentum
Exscientia capital
—
AlphaSense capital
—
No radar series.
Momentum head-to-head
Attribute tape
| Field | Exscientia | AlphaSense |
|---|---|---|
| Category | Vertical applications | Vertical applications |
| Stack | Layer 9 | Layer 9 |
| HQ | Oxford, United Kingdom | New York, NY, United States |
| Founded | 2012 | — |
| Status | Acquired | Operating |
| Funding | — | — |
| Momentum | — | — |
| Summary | Exscientia is an AI-driven pharmatech company that uses machine learning and automated experimental biology to design small-molecule drug candidates, operating a closed-loop design-make-test-learn platform. It claims to be the first company to advance AI-designed small molecules into human clinical trials, and was acquired by Recursion Pharmaceuticals in late 2024. | AlphaSense is an AI-powered market intelligence and research platform that helps business and finance professionals find, synthesize, and act on insights across earnings calls, SEC filings, equity research, expert transcripts, news, and proprietary internal content. Its generative AI and multi-agent workflows are purpose-built for investment research and competitive intelligence, producing citation-backed, analysis-ready outputs. |
| Who for | Teams evaluating AI vendors in this category. | Teams evaluating AI vendors in this category. |
| Differentiator | Exscientia is an AI-driven pharmatech company that uses machine learning and automated experimental biology to design small-molecule drug candidates, operating a closed-loop design-make-test-learn platform. It claims to be the first company to advance AI-designed small molecules into human clinical trials, and was acquired by Recursion Pharmaceuticals in late 2024. | AlphaSense is an AI-powered market intelligence and research platform that helps business and finance professionals find, synthesize, and act on insights across earnings calls, SEC filings, equity research, expert transcripts, news, and proprietary internal content. Its generative AI and multi-agent workflows are purpose-built for investment research and competitive intelligence, producing citation-backed, analysis-ready outputs. |
